Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in …

Biotechnology

US, San Carlos [HQ]

Summary
Fin. Reports
Financials
Leadership & Strategy
Government, Law & Regulation
Employees
More Analysis

Major Shareholders · Proxy Ben. Owners

Shareholders

Major Shareholders · Outstanding & Floating

Breakdown

The breakdown presents the total weighting of the relevant parties: Institutes, Insiders & Public. It's perfect to get a quick briefing regarding the shareholder structure of Vaxcyte, Inc.

Beneficial Owners Beta

Beneficial owners hold at least 10% of the stocks outstanding. Palmy retrieves this information from the most reliable, audited format which presents the data, the proxy statement.

Soon Available - Stay Tuned